The Technical Analyst
Catalyst Pharmaceuticals [CPRX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Catalyst Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-1.37% $15.13
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 783.27 mill |
| EPS: | 0.630 |
| P/E: | 24.02 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 117.86 mill |
| Avg Daily Volume: | 1.351 mill |
| RATING 2024-04-19 |
|---|
| A+ |
| Strong Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Neutral | |
| P/E: | Buy | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 24.02 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 4.09x |
| Company: PE 24.02 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 14.47 - 15.79 ( +/- 4.34%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-08 | Tierney David S | Buy | 25 000 | Common stock, par value $0.001 per share |
| 2024-04-08 | Tierney David S | Sell | 25 000 | Common stock, par value $0.001 per share |
| 2024-04-08 | Tierney David S | Buy | 25 000 | Options to purchase common stock |
| 2024-03-27 | Elsbernd Brian | Sell | 25 000 | Common stock, par value $0.001 per share |
| 2024-02-15 | Del Carmen Jeffrey | Sell | 10 667 | Restricted Stock Units |
| INSIDER POWER |
|---|
| 37.05 |
| Last 100 transactions |
| Buy: 3 182 900 | Sell: 1 448 545 |
Forecast:
16:00 - $15.15
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $15.15
Forecast 2: 16:00 - $15.15
Forecast 3: 16:00 - $15.15
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $15.13 (-1.37% ) |
| Volume | 5.29 mill |
| Avg. Vol. | 1.351 mill |
| % of Avg. Vol | 391.89 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CPRX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $13.41 | N/A | Active |
|---|
CPRX
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Last 10 Buy Signals
Latest Press Releases
2024-03-28 08:03:00 - Press Release
Catalyst Pharmaceuticals Announces Support For The Inaugural Lambert-eaton Myasthenic Syndrome (lems) Awareness Day
Coral gables, fla., march 28, 2024 (globe newswire) -- catalyst pharmaceuticals, inc. ("catalyst") (nasdaq: cprx), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult-to-treat diseases, today announced its endorsement of the inaugural lambert-eaton myasthenic syndrome ("lems") awareness day. this landmark event, now officially observed annually on march 30th, signifies a meaningful milestone for the lems community. the chosen date holds profound historical significance, coinciding with the publication of dr. edward lambert and dr. lee eaton's pioneering research on lems, which has greatly advanced the understanding and treatment of this rare neuromuscular disorder.
2024-03-27 08:03:00 - Press Release
Catalyst Pharmaceuticals To Participate In The 2024 Cantor Virtual Muscular Dystrophy Symposium
Coral gables, fla., march 27, 2024 (globe newswire) -- catalyst pharmaceuticals, inc. ("catalyst") (nasdaq: cprx), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that richard j. daly, ceo of catalyst, along with other members of catalyst's management team, will participate in the 2024 cantor virtual muscular dystrophy symposium taking place virtually on april 2-3, 2024.
2024-03-14 02:00:00 - Press Release
Santhera's Partner Catalyst Pharmaceuticals Launches Agamree® (vamorolone) In The United States
Pratteln, switzerland, march 14, 2024 – santhera pharmaceuticals (six: sann) is pleased to note the launch of agamree® (vamorolone) for the treatment of duchenne muscular dystrophy (dmd) in the united states (u.s.) by catalyst pharmaceuticals, inc. (nasdaq: cprx), the company's commercialization partner for north america.
2024-03-13 07:55:00 - Press Release
Catalyst Pharmaceuticals Announces Agamree® Now Commercially Available In The U.s. For The Treatment Of Duchenne Muscular Dystrophy (dmd)
Agamree® (vamorolone) a novel alternative corticosteroid with demonstrated properties in maintaining efficacy and a well-tolerated side effect profile
2024-03-05 08:03:00 - Press Release
Catalyst Pharmaceuticals To Participate At The Barclays 26th Annual Global Healthcare Conference
Coral gables, fla., march 05, 2024 (globe newswire) -- catalyst pharmaceuticals, inc. ("catalyst" or "company") (nasdaq: cprx), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases, today announced that richard j. daly, ceo of catalyst, along with other members of catalyst's management team, will participate at the upcoming barclays 26th annual global healthcare conference being held in miami on march 12-14, 2024.
Latest News
2024-04-05 20:29:48 - CNBC Television
Jim Cramer lays out his top small-cap healthcare picks
2024-03-29 12:37:05 - Zacks Investment Research
Why Is Catalyst (CPRX) Down 0.6% Since Last Earnings Report?
2024-03-27 07:44:00 - InvestorPlace
3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List
Biotech has seen its fair share of ups and downs, including a massive surge during the pandemic followed by a considerable dip. However, the industry will never go too far away from center stage as diseases and conditions will always need medicine and technology to treat them.
2024-03-18 20:01:33 - InvestorPlace
7 Biotech Stocks Ready to Ride the Sector's Resurgence
Why do you want to consider biotech stocks? Simply, the narrative comes down to numbers and a possible rotation.
2024-03-10 15:24:03 - InvestorPlace
3 Sexy Small-Cap Stocks to Add Sizzle to Your Portfolio
If you want big returns, you gotta think small – as in small-cap stocks. That's not to say the large-capitalization enterprises can't get you to investment Valhalla.
2024-03-05 09:30:00 - The Motley Fool
3 Biopharma Stocks You Don't Want to Miss in the New Bull Market
Vertex Pharmaceuticals is angling to treat acute pain with its new drug. Compass Pathways will have a major data update sometime in Q4.
2024-03-05 08:03:00 - GlobeNewsWire
Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference
CORAL GABLES, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases, today announced that Richard J. Daly, CEO of Catalyst, along with other members of Catalyst's management team, will participate at the upcoming Barclays 26th Annual Global Healthcare Conference being held in Miami on March 12-14, 2024.
2024-02-29 13:11:04 - Zacks Investment Research
Catalyst (CPRX) Q4 Earnings & Sales Beat Estimates, Stock Up
Catalyst (CPRX) reports encouraging fourth-quarter results, driven by Firdapse and Fycompa sales. The stock gains in the pre-market session.
2024-02-28 20:21:03 - Zacks Investment Research
Catalyst Pharmaceutical (CPRX) Tops Q4 Earnings and Revenue Estimates
Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.22 per share a year ago.
2024-02-27 08:03:00 - GlobeNewsWire
Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE
CORAL GABLES, Fla., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases, today announced an upcoming poster about the establishment of a registry to study long-term safety and quality of life (QoL) in patients with Duchenne muscular dystrophy (DMD) who are treated with AGAMREE® (vamorolone) at the upcoming 2024 MDA Clinical & Scientific Conference taking place March 3-6 in Orlando.